Iovance Biotherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-92.1M | $-52.9M | $-27.7M | $-12.0M | $-25.4M | $-3.3M | $-25.7M | $-1.6M |
| Depreciation & Amortization | $952.0K | $978.0K | $999.0K | $88.0K | $7.0K | $6.2K | $2.7K | $58.6K |
| Depreciation | $1.0M | $1.0M | $1.0M | $100.0K | $7.0K | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.0M | $18.9M | $8.5M | $3.8M | $2.8M | $2.5M | $14.6M | $114.0K |
| Net Cash from Operating Activities | $-78.7M | $-32.7M | $-18.4M | $8.6M | $-3.7M | $-2.2M | $-6.2M | $-620.8K |
| Investing Activities | ||||||||
| Capital Expenditures | $1.0M | $1.5M | $1.1M | $1.6M | $13.0K | $0 | $31.1K | $0 |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $58.7M | $8.9M | $-71.2M | — | $-12.7K | $0 | $-81.1K | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $58.7M | $96.9M | $78.3M | — | $23.3M | $1.7M | $5.5M | $1.9M |
| Net Change in Cash | $38.7M | $73.1M | $-11.3M | $25.2M | $19.7M | $-510.2K | $-782.3K | $1.3M |
| Free Cash Flow | $-79.7M | $-34.2M | $-19.5M | $7.0M | $-3.7M | $-2.2M | $-6.2M | $-620.8K |